In March AstraZeneca asked investors for $3.5 billion to fund a collaboration with Daiichi Sankyo over a new breast cancer drug – and it looks like the project is on track. AZ and Daiichi announced positive top-line results from the pivotal phase ...
Original Article: AZ and Daiichi to file new breast cancer drug after trial success